Management of oligometastatic disease in soft tissue sarcomas

Abstract

Oligometastatic soft tissue sarcoma represents an intermediate state between localized and disseminated disease. Combination A combination of surgery, radiotherapy and systemic treatment significantly improves prognosis, with a 5-year overall survival as high as 50%. Due to the high prevalence of lung metastases, most of the surgical evidence is centered around lung metastasectomy. The decision to perform surgical metastasectomy remains dependent on optimal patient selection. Adequate post-surgical lung function, absence of extrapulmonary metastases, control of the primary tumor, and feasibility of achieving negative margins are major criteria for patients to undergo successful surgery. Adequate margins, longer disease-free interval, unilateral, limited number (≤ 2), metachronous and small (< 2 cm) pulmonary metastasis are some factors associated with improved survival. Radiotherapy, especially SBRT, is an effective treatment for disease control, and its use as (neo)-adjuvant therapy has shown promising results. However, studies comparing radiotherapy against surgery are missing and the efficacy of radiotherapy independent of surgery is not yet clear. Interventional radiology techniques such as percutaneous thermal ablation (PTA) or arterial embolization have also been described as potential treatment alternatives in candidates deemed not fit for surgery. Systemic treatment has traditionally consisted of an anthracycline (doxorubicin)-based regimen with the addition of ifosfamide in certain cases. Recent advances in systemic treatment include the use of targeted therapy and immunotherapy in (oligo)-metastatic STS. However, except for certain histologies, most STS subtypes are chemoresistant, and the response to systemic treatment is poor.

Keywords

Soft tissue sarcoma / oligometastasis / surgery / treatment

References

[1] Sbaraglia M,Dei Tos AP.The 2020 WHO classification of soft tissue tumours: news and perspectives.Pathologica2021;113:70-84 PMCID:PMC8167394

[2] Siegel RL,Jemal A.Cancer statistics, 2018.CA Cancer J Clin2018;68:7-30

[3] Kawamoto T,Morishita M.Prognostic influence of the treatment approach for pulmonary metastasis in patients with soft tissue sarcoma.Clin Exp Metastasis2020;37:509-17

[4] Gadd MA,Woodruff JM,Brennan MF.Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma.Ann Surg1993;218:705-12 PMCID:PMC1243064

[5] Smith HG,Thomas JM,Strauss DC.Patterns of disease relapse in primary extremity soft-tissue sarcoma.Br J Surg2016;103:1487-96

[6] Gonzalez MR,Leon-Abarca JA.Brain metastases in patients with soft-tissue sarcomas: management and survival-a seer population-based cohort study.J Am Acad Orthop Surg Glob Res Rev2021;5:1-10 PMCID:PMC8500609

[7] Hellman S.Oligometastases.J Clin Oncol1995;13:8-10

[8] Walls GM,Fotiadis N.Treatments and outcomes in oligometastatic soft tissue soft sarcoma - a single centre retrospective analysis.Anticancer Res2021;41:5089-96

[9] Grilley-Olson JE,Demos DS,Kirsch DG.Multidisciplinary management of oligometastatic soft tissue sarcoma.Am Soc Clin Oncol Educ Book2018;38:939-48

[10] Alexander J. Pulmonary resection for solitary metastatic sarcomas and carcinomas; 1946. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20282935 [Last accessed on 12 Apr 2023]

[11] Thomford NR,Clagett OT.The surgical treatment of metastatic tumors in the lungs.J Thorac Cardiovasc Surg1965;49:357-63

[12] Marudanayagam R,Perera MT.Liver resection for metastatic soft tissue sarcoma: an analysis of prognostic factors.Eur J Surg Oncol2011;37:87-92

[13] Quiros RM.Surgical treatment of metastatic disease to the lung.Semin Oncol2008;35:134-46

[14] Margaritora S,D ‘Andrilli A.Pulmonary metastases: can accurate radiological evaluation avoid thoracotomic approach?.Eur J Cardiothorac Surg2002;21:1111-4

[15] Roth JA,Wesley MN,Putnam JB.Comparison of median sternotomy and thoracotomy for resection of pulmonary metastases in patients with adult soft-tissue sarcomas.Ann Thorac Surg1986;42:134-8

[16] Younes RN,Deheinzelin D.Surgical resection of unilateral lung metastases: is bilateral thoracotomy necessary?.World J Surg2002;26:1112-6

[17] Mangiameli G,Alloisio M.Lung Metastases: current surgical indications and new perspectives.Front Surg2022;9:884915 PMCID:PMC9098997

[18] Shiono S,Hashimoto H.Prospective study of recurrence at the surgical margin after wedge resection of pulmonary metastases.Gen Thorac Cardiovasc Surg2021;69:950-9

[19] Schur S,Lamm W.Pulmonary metastasectomy for soft tissue sarcoma-report from a dual institution experience at the Medical University of Vienna.Eur J Cancer2014;50:2289-97

[20] Predina JD,Bergey MR.Improved survival after pulmonary metastasectomy for soft tissue sarcoma.J Thorac Oncol2011;6:913-9

[21] Lee K,Lee HW.Pulmonary metastasectomy in adult patients with synovial sarcoma: a single-center experience.Korean J Thorac Cardiovasc Surg2016;49:451-5 PMCID:PMC5147470

[22] Savina M,Blay JY.Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study.BMC Med2017;15:78 PMCID:PMC5385590

[23] Nevala R,Tukiainen E.Long-term results of surgical resection of lung metastases from soft tissue sarcoma: a single center experience.J Surg Oncol2019;120:168-75

[24] Toussi MS,Dayani M,Sheibani S.Pulmonary metastasectomy and repeat metastasectomy for soft-tissue sarcoma.Asian Cardiovasc Thorac Ann2013;21:437-42

[25] Sardenberg RA,Haddad FJ,Younes RN.Pulmonary metastasectomy from soft tissue sarcomas.Clinics2010;65:871-6 PMCID:PMC2954738

[26] Chudgar NP,Munhoz RR.Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma.J Thorac Cardiovasc Surg2017;154:319-330.e1 PMCID:PMC5521256

[27] Wigge S,Steger V.Impact of surgery in patients with metastatic soft tissue sarcoma: a monocentric retrospective analysis.J Surg Oncol2018;118:167-76 PMCID:PMC6668010

[28] Casson AG,Natarajan G.Efficacy of pulmonary metastasectomy for recurrent soft tissue sarcoma.J Surg Oncol1991;47:1-4

[29] Shima Y,Ishikawa T.Aggressive surgery for liver metastases from gastrointestinal stromal tumors.J Hepatobiliary Pancreat Surg2003;10:77-80

[30] Lang H,Kaudel P,Flemming P.Hepatic metastases from leiomyosarcoma: a single-center experience with 34 liver resections during a 15-year period.Ann Surg2000;231:500-5 PMCID:PMC1421024

[31] DeMatteo RP,Fong Y,Blumgart LH.Results of hepatic resection for sarcoma metastatic to liver.Ann Surg2001;234:540-7; discussion 547 PMCID:PMC1422077

[32] Rehders A,Stoecklein NH.Hepatic metastasectomy for soft-tissue sarcomas: is it justified?.World J Surg2009;33:111-7

[33] Italiano A,Cesne AL.Trends in survival for patients with metastatic soft-tissue sarcoma.Cancer2011;117:1049-54

[34] Soyfer V,Shtraus N.Single-institution experience of SBRT for lung metastases in sarcoma patients.Am J Clin Oncol2017;40:83-5

[35] Loi M,Baker S.Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma.Radiol Med2018;123:871-8

[36] Fuller BG. The role of radiation therapy in the treatment of bone and soft-tissue sarcomas. In: Musculoskeletal cancer surgery. Kluwer Academic Publishers; 1976. pp. 85-133. Available from: https://tumorsurgery.org/Portals/0/PDF/Textbooks/ch5.pdf [Last accessed on 15 Apr 2023]

[37] Baumann BC,Kolker JD.Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: a potential alternative to resection.J Surg Oncol2016;114:65-9

[38] Mehta N,Wang PC.Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma.Sarcoma2013;2013:360214 PMCID:PMC3807836

[39] Navarria P,Cozzi L.Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma.Eur J Cancer2015;51:668-74

[40] Chang UK,Lee DH.Stereotactic radiosurgery for primary and metastatic sarcomas involving the spine.J Neurooncol2012;107:551-7

[41] Dhakal S,Milano MT.Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival.Int J Radiat Oncol Biol Phys2012;82:940-5

[42] Frakulli R,Balestrini D.Stereotactic radiotherapy in the treatment of lung metastases from bone and soft-tissue sarcomas.Anticancer Res2015;35:5581-6

[43] Thompson M.The evolving toxicity profile of SBRT for lung cancer.Transl Lung Cancer Res2019;8:48-57 PMCID:PMC6351399

[44] Modh A,Williams E.Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy.Int J Radiat Oncol Biol Phys2014;90:1168-76 PMCID:PMC4276458

[45] Folkert MR,Tom AK.Outcomes and toxicity for hypofractionated and single-fraction image-guided stereotactic radiosurgery for sarcomas metastasizing to the spine.Int J Radiat Oncol Biol Phys2014;88:1085-91

[46] Weiser MR,Leung DH.Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma.J Am Coll Surg2000;191:184-90; discussion 190

[47] Blackmon SH,Roth JA.Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival.Ann Thorac Surg2009;88:877-84; discussion 884

[48] Mohammed S,Jilani A.Primary squamous cell carcinoma of the toe masquerading as osteomyelitis: A case report aasim mohammed.Anticancer Res2015;35:6704Available from: https://ar.iiarjournals.org/content/anticanres/35/12/6695.full.pdf [Last accessed on 12 Apr 2023]

[49] Withers HR.Modeling growth kinetics and statistical distribution of oligometastases.Semin Radiat Oncol2006;16:111-9

[50] Merimsky O,Bokstein F.Radiotherapy for spinal cord compression in patients with soft-tissue sarcoma.Int J Radiat Oncol Biol Phys2004;58:1468-73

[51] Levine AM,Horasek S.Stereotactic radiosurgery for the treatment of primary sarcomas and sarcoma metastases of the spine.Neurosurgery2009;64:A54-9

[52] Thames HD.Tumor radioresponsiveness versus fractionation sensitivity.Int J Radiat Oncol Biol Phys1986;12:687-91

[53] Qasem S.Biology and treatment of metastasis of sarcoma to the brain.Front Biosci2016;8:233-44

[54] Salvati M,Frati A.Sarcoma metastatic to the brain: a series of 35 cases and considerations from 27 years of experience.J Neurooncol2010;98:373-7

[55] Aoyama H,Tago M.Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.JAMA2006;295:2483-91

[56] Slovak R,Gettinger SN,Kim HS.Immuno-thermal ablations - boosting the anticancer immune response.J Immunother Cancer2017;5:78 PMCID:PMC5644150

[57] Vanni S,Gurrieri L.Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives.Ther Adv Med Oncol2022;14:17588359221093973 PMCID:PMC9244941

[58] Palussière J,Descat E.Sarcoma lung metastases treated with percutaneous radiofrequency ablation: results from 29 patients.Ann Surg Oncol2011;18:3771-7

[59] Falk AT,Ouali M.Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group.Clin Oncol2015;27:48-55

[60] Rajan DK,Clark TW.Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization.J Vasc Interv Radiol2001;12:187-93

[61] Harding D,Brown MRD.Evaluation of quality of life outcomes following palliative treatment of bone metastases with magnetic resonance-guided high intensity focused ultrasound: an international multicentre study.Clin Oncol2018;30:233-42 PMCID:PMC5842401

[62] Bongiovanni A,Oboldi D.3-T magnetic resonance-guided high-intensity focused ultrasound (3-T-MR-HIFU) for the treatment of pain from bone metastases of solid tumors.Support Care Cancer2022;30:5737-45

[63] Vincenzi B,Schiavon G.Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options.Clin Sarcoma Res2013;3:6 PMCID:PMC3637638

[64] Meyer M.First-line therapy for metastatic soft tissue sarcoma.Curr Treat Options Oncol2019;20:6

[65] Jacobs EM.Combination chemotherapy of metastatic testicular germinal cell tumors and soft part sarcomas.Cancer1970;25:324-32

[66] Linch M,Thway K,Benson C.Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.Nat Rev Clin Oncol2014;11:187-202

[67] O ‘bryan RM,Gottlieb JE.Dose response evaluation of adriamycin in human neoplasia.Cancer1977;39:1940-8

[68] Ratan R.Chemotherapy for soft tissue sarcoma.Cancer2016;122:2952-60

[69] Edmonson JH,Blum RH.Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.J Clin Oncol1993;11:1269-75

[70] Judson I,Gelderblom H.Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.Lancet Oncol2014;15:415-23

[71] Gamboa AC,Cardona K.Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine.CA Cancer J Clin2020;70:200-29

[72] Young RJ,Lia M.Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.Acta Oncol2017;56:1013-20

[73] Eriksson M.Histology-driven chemotherapy of soft-tissue sarcoma.Ann Oncol2010;21 Suppl 7:vii270-6

[74] Carroll C,Gunsoy NB,Pokras S.Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond).Future Oncol2022;18:3651-65

[75] Gounder M,Jones RL.Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.Lancet Oncol2020;21:1423-32

[76] van der Graaf WT,Chawla SP.Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet2012;379:1879-86

[77] Henry OS,Cerniglia KS.Tyrosine kinase inhibitors versus radiation therapy in unresectable dermatofibrosarcoma protuberans (DFSP): a narrative systematic review.Am J Surg2023;225:268-74

[78] Kasper B,Hohenberger P.Desmoid tumors: clinical features and treatment options for advanced disease.Oncologist2011;16:682-93 PMCID:PMC3228186

[79] Paoluzzi L.Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: a review.JAMA Oncol2019;5:254-60

[80] Khan J,Waheed A.Gastrointestinal stromal tumors (GIST): a population-based study using the SEER database, including management and recent advances in targeted therapy.Cancers2022;14:3689 PMCID:PMC9367571

[81] Schaefer IM,Serrano C.The GIST of advances in treatment of advanced gastrointestinal stromal tumor.Am Soc Clin Oncol Educ Book2022;42:1-15 PMCID:PMC9113521

[82] Drilon A,Kummar S.Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children.N Engl J Med2018;378:731-9 PMCID:PMC5857389

[83] Rabban JT,Sangoi AR.NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma.Histopathology2020;77:100-11

[84] Recine F,Fausti V.Case report: adult NTRK-rearranged spindle cell neoplasm: early tumor shrinkage in a case with bone and visceral metastases treated with targeted therapy.Front Oncol2021;11:740676 PMCID:PMC8776642

[85] Damerell V,Prince S.Molecular mechanisms underpinning sarcomas and implications for current and future therapy.Signal Transduct Target Ther2021;6:246 PMCID:PMC8241855